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Tumor necrosis factor (TNF) is a cytokine that mediates many pathophysiologial processes, including
angiogenesis. However, the molecular signaling involved in TNF-induced angiogenesis has not been deter-
mined. In this study, we examined the role of Etk/Bmx, an endothelial/epithelial tyrosine kinase involved in cell
adhesion, migration, and survival in TNF-induced angiogenesis. We show that TNF activates Etk specifically
through TNF receptor type 2 (TNFR2) as demonstrated by studies using a specific agonist to TNFR2 and
TNFR2-deficient cells. Etk forms a preexisting complex with TNFR2 in a ligand-independent manner, and the
association is through multiple domains (pleckstrin homology domain, TEC homology domain, and SH2
domain) of Etk and the C-terminal domain of TNFR2. The C-terminal 16-amino-acid residues of TNFR2 are
critical for Etk association and activation, and this Etk-binding and activating motif in TNFR2 is not
overlapped with the TNFR-associated factor type 2 (TRAF2)-binding sequence. Thus, TRAF2 is not involved
in TNF-induced Etk activation, suggesting a novel mechanism for Etk activation by cytokine receptors.
Moreover, a constitutively active form of Etk enhanced, whereas a dominant-negative Etk blocked, TNF-
induced endothelial cell migration and tube formation. While most TNF actions have been attributed to
TNFR1, our studies demonstrate that Etk is a TNFR2-specific kinase involved in TNF-induced angiogenic
events.
Angiogenesis, a process of new blood vessel formation, is
involved in many physiological and pathological settings, such
as ischemia, atherosclerosis, and arthritis (7, 62). Although
angiogenic factors such as VEGF and FGF promote angiogen-
esis in vitro and in vivo, inflammatory responses (as defined by
the presence of infiltrated macrophages and proinflammatory
cytokines) seem to be essential for angiogenesis (2, 28). In-
flammatory angiogenesis is largely mediated by proinflamma-
tory cytokines, such as tumor necrosis factor (TNF), which has
been shown to stimulate angiogenesis in vitro, in vivo, and in
disease settings (18, 27, 44, 48). However, the molecular sig-
naling involved in TNF-induced angiogenesis has not been
determined.
Vascular endothelial cells (EC) are among the principal
physiological targets of TNF (37). In EC, as in other cell types,
TNF elicits a broad spectrum of biological effects, including
proliferation, differentiation, and apoptosis (31, 32, 49, 51).
The nature of TNF effects depends on TNF concentration and
the type and growth state of the target cells (17). These dif-
ferences in TNF-induced response are due, in part, to the
presence of two distinct TNF-specific plasma membrane-local-
ized receptors, type 1 55-kDa TNFR (TNFR1) and type 2
75-kDa TNFR (TNFR2) (61). TNFR1 is expressed ubiqui-
tously, whereas TNFR2 expression is tightly regulated and
found predominantly on EC and hemopoietic cells (58). In
many cell types, including EC, TNFR2 is primarily expressed
on the cell surface, whereas TNFR1 is predominantly localized
to the Golgi with little surface expression (6). The concept of
ligand passing has been proposed in which plasma membrane
TNFR2 binds TNF and efficiently passes the anchored ligand
to TNFR1 (55). It has also been proposed that TNFR2 pri-
marily responds to TNF expressed as an integral membrane
protein on the cell surface, whereas TNFR1 primarily responds
to soluble TNF (21, 22). However, recent evidence supports
the idea that TNF utilizes TNFR1 and TNFR2 to trigger dis-
tinct signaling events and exert diverse biological functions in
a context-dependent manner. TNFR1 is believed to mediate
cell death, whereas TNFR2 serves to enhance TNFR1-induced
cell death or to promote cell activation, migration, growth, or
proliferation (9, 14, 15, 19, 35, 36, 45, 52, 56, 63). The role of
TNFR2 in TNF signaling in EC is not clear. Studies utilizing
receptor-specific neutralizing antibodies have shown that
TNFR2 contributes to effects of lower concentrations of TNF
(50). Furthermore, it has been shown that lower TNF concen-
trations stimulate proliferation and migration through TNFR2,
whereas higher TNF concentrations inhibit both these re-
sponses through TNFR1 in EC and epithelial cells (23, 26).
TNFR1 and TNFR2, among members of the TNF receptor
family, share a similar architecture with characteristic cysteine-
rich motifs (52). Unlike the extracellular domains, the primary
amino acid sequences of the cytoplasmic domains of TNFR1
and TNFR2 are unrelated. It is believed that the two receptors
initiate distinct signal transduction pathways by interacting
with different signaling proteins (12, 20, 29). A present model
postulates that TNF binding triggers trimerization of TNFR1
and TNFR2, which recruit adaptor proteins and signaling mol-
ecules by their intracellular domains to form a receptor-signal-
ing complex (4, 60). Many proteins have been shown to be
recruited by TNFR1, including TRADD (TNFR-associated
death-domain protein) (24, 25). TRADD functions as a plat-
form adaptor that recruits TRAF2 (TNFR-associated factor),
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RIP (receptor-interacting protein kinase), and FADD (Fas-
associated death-domain protein) to form TNFR1 signaling
complex and to activate several distinct signaling cascades (11,
47, 53). TRAF2 acts as an assembly platform for the recruit-
ment of additional factors, including the members of MAP
kinase kinase kinase family, leading to activation of the JNK
pathway (5).
In contrast, less is known regarding proteins recruited to
TNFR2 and downstream signaling. Like TNFR1, TNFR2 can
also recruit TRAF2 and utilize TRAF1 and the two cellular
inhibitors of apoptotic proteins (cIAP1 and cIAP2) (46). How-
ever, the role of these factors in TNFR2-specific signaling has
not been defined. So far no other signaling molecules have
been shown to directly associate with TNFR2, and it is not
known whether TRAF2-independent signaling pathways exist
for TNFR2.
The endothelial/epithelial tyrosine kinase (Etk/Bmx), a
member of the Btk nonreceptor tyrosine kinase family, has
been implicated in cell adhesion, migration, proliferation, and
survival (39, 40, 42, 54). Etk and three other members of this
family, (Btk, Itk, and Tec) participate in signal transduction
stimulated by growth factor receptors, cytokine receptors, G-
protein-coupled receptors, antigen receptors, and integrins
(10, 33, 41, 57). They share common structural domains, in-
cluding a pleckstrin homology (PH) domain, a TEC homology
(TH) domain, which has a PXXP motif (with exception of
Etk), SH3 and SH2 domains, and a kinase domain. The mech-
anism(s) by which Btk family kinases are activated is not clear.
It has been proposed that intramolecular interactions between
the PXXP motif in the TH domain and the SH3 domain (with
the exception of Etk) and between the PH domain and the
kinase domain fold Btk family kinases into a closed inactive
form. Btk activation occurs when stimuli disrupt these intramo-
lecular interactions by promoting Btk translocation to the
plasma membrane (10, 33, 38–42, 57).
Recently Etk has been implicated in the signaling of Tie-2
and VEGF receptors, two important receptor families essen-
tial for angiogenesis (41). In the present study we examined the
role of Etk in TNF-induced angiogenesis. We show that TNF
activates Etk through TNFR2 in a TRAF2-independent man-
ner. TNFR2 associates with Etk through the C-terminal 16-
amino-acid sequence of TNFR2 and multiple domains (the
PH, TH, and SH2 domains) of Etk. Furthermore, we show that
a constitutively active Etk mutant enhanced, whereas a domi-
nant-negative Etk mutant blocked, TNF-induced angiogenesis
by using in vitro models of EC migration and tube formation.
FIG. 1. TNF activates Etk specifically through TNFR2. (a) TNFR2 (R2) agonist, but not TNFR1 (R1) agonist, activates Etk in EC. BAEC were
treated with human TNF (1 ng/ml), anti-TNFR1 (R1; 5 g/ml), anti-TNFR2 TNFR1 (R2; 5 g/ml), or a normal goat serum (5 g/ml; NS;
TNFR1) for 15 min or were left untreated. Etk activation was detected by immunoprecipitation with anti-Etk followed by Western blot with
antiphosphotyrosine (pY). Total Etk was detected by Western blot with anti-Etk. IgG, immunoglobulin G; IB, immunoblot.(b) JNK activation was
determined by an in vitro kinase assay with GST-c-Jun as a substrate. JNK1 protein in the immunoprecipitates was determined by Western blot
with anti-JNK1. (c and d) TNF fails to activate Etk in TNFR2-deficient cells. Lung EC from wild type (WT), TNFR1/, or TNFR1/TNFR2/
mice were treated with murine TNF at 1 ng/ml for 15 min, and Etk (c) and JNK (d) activation was determined.
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Our data demonstrate that Etk is a critical mediator in TNF-
induced angiogenic events through association with TNFR2.
MATERIALS AND METHODS
Plasmids. Mammalian expression plasmids for the wild-type and the domi-
nant-negative TRAF2 (WT-TRAF2 and DN-TRAF2, respectively) were pro-
vided by David Goeddel (Tularik); plasmids for Etk/Bmx wild type and mutants
were provided by Dianqing Wu (University of Connecticut); and plasmids for
TNFR1, TNFR2, and TNFR2 deletion mutants were provided by Jordan S.
Pober (Yale University). The TNFR2 and Etk point mutants were generated by
the Quickchange site-specific mutagenesis kit following the manufacturer’s in-
structions (Stratagene). Etk-DK, -SK, -K, and -PTH were constructed into Flag-
vector (Clontech). Etk-SK and Etk-DK were also cloned into an internal ribo-
some entry sequence vector coexpressing enhanced green fluorescence protein in
a bicistronic mRNA (pIRES; Clontech).
Cells and cytokines. Human umbilical vein EC (HUVEC) and bovine aorta
endothelial cells (BAEC) were purchased from Clonetics (San Diego, Calif.).
Lung endothelial cells isolated from TNFR-deficient mice (14, 35, 45) (The
Jackson Laboratory) were isolated according to a procedure described previously
(43). Minced tissue was digested with collagenase. Large tissue fragments were
removed by filtration through a 100-m nylon screen. The filtrate was collected on
a 20-m nylon screen, washed, and purified by Percoll gradient centrifugation. EC
contained in the 3rd through 10th fractions from the top of the gradient (density,
1.00 to 1.050 g/ml) were collected, washed, and seeded into dishes containing EC
growth medium. Contaminating non-EC were removed by mechanical weeding
and by fluorescence-activated cell sorting with antibodies to PECAM-1 (CD31)
to label the EC. The sorted cells were assessed for EC phenotype, including
morphology and expression of von Willebrand Factor and PECAM-1. EC were
used at passages 1 to 5. Human and murine recombinant TNF and polyclonal
antibodies against TNFR1 and TNFR2 were from R&D Systems (Minneapolis,
Minn.).
Transfection. Transfection of BAEC was performed with Lipofectamine 2000
according to the manufacturer’s protocol (Gibco). Cells were cultured at 90%
confluence in 6-well plates and were transfected with a total of 4 g of plasmid
constructs as indicated. Cells were harvested at 36 to 48 h posttransfection, and
cell lysates were used for protein assays.
JNK kinase assay. JNK assays were performed as described previously by
using GST-c-Jun(1-80) fusion protein as a substrate (34). Briefly, a total of 400
g of cell lysates was immunoprecipitated with 5 g of antibody against JNK1
(Santa Cruz). The immunoprecipitates were mixed with 10 g of GST-c-Jun(1-
80) suspended in the kinase buffer (20 mM HEPES [pH 7.6], 20 mM MgCl2, 25
mM -glycerophosphate, 100 M sodium orthovanadate, 2 mM dithiothreitol,
20 M ATP) containing 1 l (10 Ci) of [-32P]ATP. The kinase assay was
performed at 25°C for 30 min. The reaction was terminated by the addition of
Laemmli sample buffer, and the products were resolved by sodium dodecyl
sulfate–12% polyacrylamide gel electrophoresis followed by protein transferring
to a membrane (Immobilon P; Millipore, Milford, Mass.). Phosphorylated GST-
c-Jun(1-80) was visualized by autoradiography. The membrane was further used
for Western blotting with anti-JNK1.
Immunoprecipitation and immunoblotting. After various treatments BAEC
were washed twice with cold phosphate-buffered saline (PBS) and were har-
vested in a membrane lysis buffer (30 mM Tris [pH 8], 10 mM NaCl, 5 mM
EDTA, 10 g of polyoxyethylene-8-lauryl ether/liter, 1 mM O-phenanthroline, 1
mM indoacetamide, 10 mM NaF, 5 mM orthovanadate, 10 mM sodium pyro-
phosphate). Cells were immediately frozen in liquid nitrogen. Cell lysates were
then thawed on ice, scraped, sonicated, and centrifuged at 14,000  g at 4°C for
15 min. Supernatants were used immediately for immunoblot or immunopre-
cipitation. For immunoprecipitation to analyze protein interaction in vivo, su-
pernatant of cell lysates was diluted three times with a cold lysis buffer (50 mM
Tris-HCl [pH 7.6], 150 mM NaCl, 0.1% Triton X-100, 0.75% Brij 96, 1 mM
sodium orthovanadate, 1 mM sodium fluoride, 1 mM sodium pyrophosphate, 10
g of aprotinin/ml, 10 g of leupeptin/ml, 2 mM phenylmethylsulfonyl fluoride,
1 mM EDTA). The lysates were then incubated with the first protein-specific
antiserum (e.g., anti-Etk from Santa Cruz or anti-TNFR from R&D) for 2 h with
50 l of GammaBind plus Sepharose. Immune complexes were collected after
each immunoprecipitation by centrifugation at 13,000  g for 10 min followed by
three to five washes with lysis buffer. The immune complexes were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immuno-
blot (Immobilon P) with the second protein (e.g., phosphotyrosine antibody;
Upstate Biotechnology Inc., Lake Placid, N.Y.). The chemiluminescence was
detected by using an ECL kit according to the instructions of the manufacturer
(Amersham Life Science, Arlington Heights, Ill.). For detection of Flag-tagged
proteins (Etk or TNFR2 mutants), anti-Flag M2 antibody (Sigma) was used for
FIG. 2. Association of TNFR2 with Etk in EC is ligand independent. BAEC were either treated with TNF (1 ng/ml for 15 min) or were left
untreated. An antibody against either Etk, TNFR1, or TNFR2 was used to examine its ability to precipitate a complex of Etk and TNFRs. A total
of 40 g of cell lysate and 6 g of antibody was used for each immunoprecipitation (IP). (a) Etk associates with TNFR2 but not with TNFR1 in
EC. Anti-Etk was used as a positive control for immunoprecipitation. (b) Association of Etk with TNFR2 is TNF independent in EC. Normal goat
sera (NS) were used as controls. IgG, immunoglobulin G; IB, immunoblot; R1, TNFR1; R2, TNFR2.
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FIG. 3. Multiple domains (the PH, TH, and SH2 domains) of Etk are responsible for association with TNFR2 in EC. (a) Schematic diagram
of Etk domains and expression constructs. The kinase-dead Etk (Etk-KD) has a mutation at the kinase domain (K444Q). The dominant-negative
Etk (Etk-DN) has mutations at the kinase domain (K444Q) and the phospholipid-binding PH domain (E42K). Etk-SH3 has a deletion of the
SH3 domain. Etk-SK contains the SH2 and the kinase domains. Etk-K contains the kinase domain only. Etk-PTH contains the PH and TH
domains. Etk-DK has a deletion of the kinase domain. Etk-N contains the PTH and SH3 domains. Etk-SH3/2 contains the SH3 and SH2 domains.
A summary of interaction with TNFR2 is shown on the right. Etk-WT, wild-type Etk; aa, amino acid. (b) Mapping the Etk domain interacting with
TNFR2. Flag-tagged Etk-SK, Etk-K, Etk-PTH, and Etk-DK were transfected in EC, and expression was determined by anti-Flag. Interaction of
Etk domains with TNFR2 was examined by immunoprecipitation with TNFR2 or normal serum (NS) followed by Western blot with anti-Flag as
indicated. TNFR2 protein in the immunoprecipitate was detected by Western blot with anti-TNFR2. (c) Mapping the TNFR2-interacting domain
in the N-terminal portion of Etk. Flag-tagged TNFR2 was cotransfected in EC with Etk-DK, Etk-N, or Etk-SH3/2. Expression was determined by
anti-Flag (lanes 1 to 3). Interaction of Etk domains with TNFR2 was determined by immunoprecipitation with TNFR2 followed by Western blot
with anti-Flag (lanes 4 to 6). (d) Determining the role of the SH3 domain in Etk for TNFR2 association. T7-tagged Etk-WT, DN, and Etk-SH3
were cotransfected with Flag-TNFR2 in EC, and interaction of Etk with TNFR2 was examined by immunoprecipitation with TNFR2 followed by
Western blot with anti-T7. TNFR2 was detected by Western blot with anti-Flag. IP, immunoprecipitation; IB, immunoblot; R2, TNFR2.
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FIG. 4. The C-terminal 16-amino-acid residues in TNFR2 are critical for association and activation of Etk. (a) Schematic diagram of TNFR2
domains and the deletion mutants at the C terminus. TNFR2(16) and TNFR2(37) are mutants lacking 16- and 37-amino-acid residues at the
C terminus, respectively. The black box indicates the TRAF2-binding domain. TNFR2(mTR2) is a mutant containing mutations at the TRAF2-
binding motif. All TNFR2 expression constructs are Flag-tagged at the N termini. (b) Flag-tagged Etk-DK or the VC was cotransfected in EC with
TNFR2 expression constructs, and expression was determined by anti-Flag. (c) Interaction of Etk-DK with full-length TNFR2 and TNFR2(mTR2)
but not with TNFR2(16) or TNFR2(37). Interaction was determined by immunoprecipitation with anti-TNFR2 (recognizes the extracellular
domain of TNFR2) followed by Western blot with anti-Flag. (d) Interaction of TRAF2 with TNFR2-WT but not with TNFR2(mTR2) or
TNFR2(37). Flag-tag TNFR2-WT, TNFR2(mTR2), or TNFR2(37) was cotransfected in EC with a TRAF2 expression construct. Association
of TRAF2 with TNFR2 or TNFR2(37) was determined by immunoprecipitation with anti-TNFR2 followed by Western blot with anti-TRAF2.
(e) Association of Etk with TNFR2 mutants. BAEC were transfected with T7-tag Etk-WT and Flag-TNFR2 constructs (WT, 16, or mTR2) as
indicated. Association of Etk with TNFR2 proteins was determined by immunoprecipitation with anti-TNFR2 followed by Western blot with
anti-T7. TNFR2 protein was determined by Western blot with anti-Flag. (f) Activation of Etk by TNFR2 mutants. Etk activation was determined
by immunoprecipitation with anti-T7 followed by Western blot with anti-pY. Total Etk was determined by Western blot with anit-T7. (g) Schematic
diagram of Etk-binding/activating motif and TRAF2-binding motif in the C-terminal intracellular domain of human and murine TNFR2. The
Etk-binding/activating motif is highly conserved between the human and murine TNFR2 and differs in only one residue (in bold). IP, immuno-
precipitation; IB, immunoblot; R2, TNFR2; aa, amino acid.
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immunoblotting. For detection of T7-tagged proteins (Etk mutants), anti-T7
antibody (Novagen) was used for immunoblotting.
EC migration assay and image analysis. BAEC were cultured in 0.5% fetal
bovine serum (FBS) overnight and were subjected to wound injury with a yellow
tip. Cells were washed with PBS once, and fresh medium (0.5% FBS) with or
without TNF (1 ng/ml) was added. Cells were further cultured for the indicated
times. The EC migration in culture was determined by measuring wound areas in
cell monolayers. Three different images from each well along the wound were
captured by a digital camera under a microscope (magnification, 4). A hemo-
cytometer (1 mm2/grid) was used as a standard. The wound area was measured
(in square millimeters) and analyzed by using NIH Image 1.60.
EC tube formation assay in collagen gel culture. Collagen gel culture was
performed as follows. The ingredients 10 RPMI 1640 (Gibco), neutralizing
buffer (260 mmol of NaHCO3/liter, 200 mmol of HEPES/liter, 50 mmol of
NaOH/liter) and collagen gel (Vitrogen) were mixed at the ratio of 1:1:8 on ice
and then were added to a 24-well plate (400 l/well); the plate was then incu-
bated at 37°C for 1 h. BAEC cells were seeded at 2  104/well, and the plate was
incubated overnight in 5% CO2 at 37°C. The medium was removed and cells
were gently washed with 1 PBS. The collagen gel mixture prepared as described
above was added onto the cells, which had already attached to the first layer of
collagen gel. The plate was incubated for 30 min at 37°C (while keeping the plate
away from CO2). EC media were added at 500 l/well, and the plates were
incubated in 5% CO2 at 37°C. EC media were changed every 2 to 3 days, and
tube formation was observed after 36 to 48 h. A branched EC network was
visualized under a microscope. Images from three different areas in each well
were captured by a digital camera under a microscope (magnification, 4), and
the area covered by branched cells was measured (in square millimeters) and
analyzed by NIH Image 1.60.
RESULTS
TNF activates Etk through TNFR2. Recently it was observed
that Etk activity was increased in human TNF transgenic mice,
suggesting a role for Etk in TNF signaling (64 and W. Min,
unpublished data). To determine if TNF activates Etk,
HUVEC were treated with TNF (1 ng/ml for 15 min) or an
antibody against TNFR (5 g/ml for 15 min). TNFR1 antibody
and TNFR2 antibody specifically recognize the extracellular
domain of the receptor and can function as receptor agonists
(15, 19, 56). Etk activation was determined by measuring ty-
rosine phosphorylation of Etk. Results show that TNF and
TNFR2 agonist activated Etk. However, TNFR1 agonist did
not activate Etk, suggesting that TNF activates Etk through
TNFR2 (Fig. 1a). As a control, JNK activity was also measured
by an in vitro kinase assay. As expected, TNF, TNFR1 agonist,
and TNFR2 agonist all activated JNK (Fig. 1b). Similar results
were obtained with BAEC (data not shown). To define further
the role of TNFR2 in Etk activation, TNF-induced Etk acti-
vation in EC from mice deficient in TNFR1 or both TNFR1
and TNFR2 was examined. Results show that TNFR1 defi-
ciency had no effect on Etk activation compared to that of
wild-type cells. However, double deficiency (TNFR1/R2/)
(14, 35, 45) resulted in diminished Etk activation in response to
TNF (Fig. 1c). In contrast, JNK activation by TNF was blunted
in both cell types compared to that of the wild type (Fig. 1d),
indicating that TNFR1 is required for JNK but not for Etk
activation by TNF. Taken together these data demonstrate that
TNF activates Etk specifically through TNFR2 in EC.
Etk binds to TNFR2 but not TNFR1. To define the mecha-
nisms by which TNFR2 activates Etk, we examined association
of endogenous Etk and TNFR2 in EC (both HUVEC and
BAEC). Interaction of Etk with TNFR1 and TNFR2 was de-
termined by coimmunoprecipitation assay. The ability of an
antibody against either Etk or TNFR2 to precipitate a complex
of Etk and TNFR2 suggests that Etk and TNFR2 interact in
vivo (Fig. 2a). In contrast, Etk and TNFR1 failed to be coim-
FIG. 4—Continued.
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munoprecipitated by either anti-Etk or anti-TNFR1 (Fig. 2a),
indicating that Etk and TNFR1 do not interact. To determine
if association of Etk with TNFR2 is TNF-dependent, HUVEC
were treated with TNF. Association of Etk with TNFR2 was
examined by coimmunoprecipitation assay, as described above,
with anti-TNFR2 or anti-Etk (Fig. 2b). Results showed that
TNF did not enhance the association of Etk with TNFR2,
indicating that Etk interacts with TNFR2 in a ligand-indepen-
dent fashion (Fig. 2b). Similar results for TNFR2-Etk interac-
tion were obtained with BAEC. These results indicate that
HUVEC and BAEC share a common pathway for TNF-in-
duced Etk activation.
Multiple domains (PH, TH, and SH2) of Etk are critical for
association with TNFR2. Etk contains several structural do-
mains (PH, TH, SH3, SH2, and kinase domains; Fig. 3a). To
map the domain of Etk responsible for interaction with
TNFR2, we generated Flag-tagged expression constructs en-
coding different Etk structural domains, as shown in Fig. 3a.
Etk-SK contains the SH2 domain and the kinase domain,
Etk-K contains the kinase domain only, Etk-PTH contains the
PH and TH domains, and Etk-DK has a deletion of the kinase
domain. Interaction of Etk proteins with endogenous TNFR2
was performed by coimmunoprecipitation with anti-TNFR2
followed by Western blot with anti-Flag. Results showed that
Etk-DK, but not Etk-SK, -K, or -PTH, interacts with TNFR2
(Fig. 3b). These data suggest that TNFR2-interacting sequence
is located in the N-terminal (from PH to SH2) domains of Etk.
To further map the interacting domain in Etk, we used
Etk-DK to generate expression constructs for Etk-N (the PTH
and SH3 domains) and Etk-SH3/2 (the SH3 and SH2 do-
mains). BAEC were cotransfected with Flag-tagged Etk mu-
tants and TNFR2 constructs, and interaction of Etk proteins
with TNFR2 was performed by coimmunoprecipitation with
anti-TNFR2 followed by Western blot with anti-Flag. Results
showed that Etk-DK, but not Etk-N or Etk-SH3/2, associated
with TNFR2 (Fig. 3c). These data suggest that either all do-
mains (PTH, SH3, and SH2) or a combination of the PTH and
SH2 domains are required for TNFR2 association.
To define the role of the SH3 domain in TNFR2 binding, we
generated Etk-SH3 (deletion of the SH3 domain) from Etk-
WT. BAEC were transfected with various T7-tagged Etk ex-
pression constructs (Etk-WT, -DN, and -SH3) and Flag-
TNFR2, and interaction of Etk proteins with TNFR2 was
performed by coimmunoprecipitation with anti-TNFR2 fol-
lowed by Western blot with anti-T7. The kinase-dead Etk (Etk-
KD) has a mutation at the kinase domain (K444Q). The dom-
inant-negative form (Etk-DN) has mutations at both the kinase
domain (K444Q) and the phospholipid-binding PH domain
(E42K) (Fig. 3a). Results showed that Etk-DN and Etk-SH3
bound to TNFR2 as well as Etk-WT did (Fig. 3d), indicating
that the Etk kinase activity and phospholipid-binding activity
are not required for interaction with TNFR2. The SH3 domain
is not required for TNFR association. Taken together, we
conclude that the combination of multiple domains (the PH,
TH, and SH2 domains) in Etk is critical for Etk-TNFR2 com-
plex formation.
A non-TRAF2-binding motif at the C-terminal domain (16-
amino-acid residues) in TNFR2 is critical for Etk association
and activation. To map the residues in the intracellular domain
of TNFR2 important for Etk binding, Flag-TNFR2 mutants
containing truncated C termini were used (16). TNFR2(16)
and TNFR2(37) are mutants lacking 16- and 37-amino-acid
residues at the C terminus, respectively (Fig. 4a). We also
constructed a TNFR2 mutant in which the TRAF2-binding
motif SKEE has been changed to AKAA (mTR2; Fig. 4g). EC
were transfected with Etk-DK and TNFR2 expression con-
structs (Fig. 4b). Interaction of Etk-DK with TNFR2 proteins
was performed as described in Materials and Methods. Results
showed that the full-length TNFR2-wild type (WT) and the
TRAF2-binding motif mutant (mTR2), but not TNFR2(16)
or TNFR2(37), interacted with Etk-DK (Fig. 4c). A similar
result was observed for Etk-WT (see Fig. 4e). Consistent with
previous reports (47), TNFR2-WT, but not TNFR2(37) (de-
letion of the TRAF2-binding motif) or TNFR2(mTR2) (mu-
tations at the TRAF2-binding motif SKEE), bound to TRAF2
(Fig. 4d). These data suggest that Etk associates with TNFR2
through a non-TRAF2-binding motif.
To determine if association of TNFR2 with Etk is required
for Etk activation, we examined Etk activation by TNFR2
mutants. BAEC were cotransfected with Etk with TNFR2-WT,
TNFR2(mTR2), or TNFR2(16). Association of Etk with
TNFR2 was determined by immunoprecipitation with anti-
Flag (for TNFR2) followed by Western blot with anti-T7 (for
Etk). Activation of Etk by TNFR2 was determined by Etk
tyrosine phosphorylation. As expected, wild-type TNFR2
bound to and activated Etk (lane 1 in Fig. 4e and f).
TNFR2(mTR2) (TRAF2-binding deficient) still retains the
ability to bind and activate Etk (lane 2 in Fig. 4e and f), further
supporting the hypothesis that TNFR2 activates Etk in a
TRAF2-independent manner. In contrast, TNFR2(16) was
unable to associate and activate Etk (lane 3 in Fig. 4e and f),
suggesting that association of Etk with TNFR2 is required for
Etk activation. These data define the C-terminal 16 residues
(amino acids 445 to 461 in human TNFR2) as an Etk-binding/
activating motif. Interestingly, this Etk-binding/activating motif
is highly conserved between the human and murine TNFR2,
and only one residue differs (M456 in human and A456 in
murine molecules) (Fig. 4g). However, the sequences between
the TRAF2-binding motif and the Etk-binding/activating motif
are quite variable. These results warrant further mutagenesis
analysis to define the critical residues in TNFR2 sequence for
Etk binding and activation.
TRAF2 is not involved in Etk activation by TNF. TRAF2 is
an adaptor protein that was shown to be recruited by both
TNFR1 and TNFR2 and that couples TNF signaling to NF-	B
and JNK activation (46, 47). The N-terminal domain of
TRAF2, containing the ring and zinc fingers, is critical for its
activity. A dominant-negative TRAF2 (DN-TARF2) contains
the TRAF domain but lacks the functional N terminus and
presumably acts by competing with endogenous TRAF2 for
binding to receptors or receptor complexes (47). To determine
the role of TRAF2 in Etk activation by TNF and/or TNFR2,
we examined effects of TRAF2 on TNF-induced Etk activa-
tion. EC were transfected with an expression construct for
WT-TRAF2 or DN-TRAF2 (Fig. 5a). Consistent with previous
observations (34), TRAF2 expression alone activated JNK in
EC, whereas DN-TRAF2 blocked TNF-induced JNK activa-
tion (Fig. 5b). In contrast, expression of WT-TRAF2 did not
activate Etk and DN-TRAF2 had no effect on TNF-induced
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Etk activation (Fig. 5c). These data indicate that Etk activation
by TNF is TRAF2 independent.
A critical role of Etk in TNF-induced angiogenesis. Etk has
been implicated in cell migration and tumor metastases (3, 10).
To examine the biological consequence of Etk activation by
TNF in EC, we reasoned that Etk might be involved in TNF-
induced angiogenesis. To test this hypothesis, we employed in
vitro angiogenesis models to determine effects of Etk on TNF-
induced EC migration and tube formation, two critical steps in
the process of angiogenesis. First we generated two Etk mu-
tants: Etk-SK contains the SH2 domain and the kinase domain,
and Etk-DK contains a deletion of the kinase domain (see Fig.
3a). Etk-SK and Etk-DK were coexpressed with an enhanced
green fluorescent protein in a bicistronic mRNA, linked by an
internal ribosome entry sequence. BAEC were transfected
with Etk-SK and Etk-DK by using Lipofectamine 2000. Trans-
fection efficiency was determined by fluorescence microscopy
and usually reached 90%. This high transfection efficiency al-
lowed us to examine effects of the transgene on endogenous
Etk activity (30) (Fig. 5). Expression of Etk-DK and Etk-SK
was determined by Western blot anti-Flag (Fig. 6a). It has been
proposed that an intramolecular interaction between the PH
domain and the kinase domain folds Etk into a closed inactive
form. Thus, the PH domain is an inhibitory domain and dele-
tion of the PH domain (Etk-SK) should render Etk active. It is
conceivable that overexpressed Etk-SK binds to the PH do-
main of endogenous Etk to release the inhibitory PH domain
from Etk, leading to Etk activation. In contrast, overexpressed
Etk-DK (containing the inhibitory PH domain) should keep
endogenous Etk in an inactive form. We examined the effect of
Etk-SK and Etk-DK on TNF-induced endogenous Etk phos-
phorylation. Results showed that Etk-SK increased both basal
and TNF-induced phosphorylation of endogenous Etk, sug-
gesting that Etk-SK is a constitutively active form (Fig. 6b and
c). In contrast, Etk-DK blocked TNF-induced activation of
endogenous Etk (Fig. 6b), indicating that Etk-DK is a domi-
nant-negative form. As expected, we did not observe phos-
phorylation of Etk-SK (lacking Y40 in the PH domain) or
Etk-DK (lacking the kinase domain) (data not shown).
Next we examined effects of Etk-DK or Etk-SK expression
on EC migration induced by wounding. EC were cultured in a
medium with 0.5% FBS for 24 h followed by a wound healing
assay in the presence of various concentrations of TNF (0, 1, 5,
and 10 ng/ml). Consistent with previous reports on TNF-in-
duced angiogenesis (18, 27, 44, 48), we found that TNF at a low
concentration (1 ng/ml) stimulated EC migration to heal the
wound (Fig. 6c). However, TNF at high concentrations (5 and
10 ng/ml) inhibited EC migration (data not shown). The effects
of Etk-SK and Etk-DK expression on TNF-induced EC migra-
tion rates were determined by measuring the wound area (in
square millimeters/field) in the cell monolayer at various time
points after wounding (0, 12, and 24 h). Results showed that
Etk-SK expression stimulated basal (TNF) and TNF-induced
(TNF) EC migration (Fig. 6c and d). In contrast, Etk-DK
significantly delayed TNF-induced EC wound healing com-
pared to that for vector control (VC)-infected cells (Fig. 6c and
d). These data indicate that Etk is involved in TNF-induced
EC migration.
Finally, we examined the effects of Etk-DK or Etk-SK ex-
pression on TNF-induced EC tube formation. EC were cul-
tured in 0.5% FBS medium in a three-dimensional collagen
gel. TNF had a dose effect on EC tube formation similar to that
observed in the EC migration assay (data not shown). TNF at
1 ng/ml stimulated tube formation as indicated by the EC
network structure (Fig. 6e). The effects of Etk-SK and Etk-DK
expression on TNF-induced tube formation were determined
by measuring areas covered by the branched cell network (in
square millimeters/field) on day 5 after addition of the second
layer of collagen gel. Results showed that expression of
Etk-DK reduced, whereas Etk-SK enhanced, TNF-induced
tube formation (Fig. 6e and f). These data demonstrate that
Etk is a critical mediator in TNF-induced EC tube formation.
DISCUSSION
In this study we show that TNF activates Etk specifically
through TNFR2, as demonstrated by studies using a specific
agonist to TNFR2, overexpression of TNFR2, and TNFR2-
deficient cells. Etk binds to a non-TRAF2-binding motif in
TNFR2 intracellular domains and is activated by TNF in a
FIG. 5. TRAF2 is not involved in TNF-induced Etk activation in
EC. BAEC were transfected with WT-TRAF2 or DN-TRAF2. Expres-
sion of TRAF2 was determined by Western blot with anti-Flag (a).
Twenty-four hours posttransfection, cells were treated with human
TNF (1 ng/ml for 15 min) or were left untreated. Etk (b) and JNK (c)
activation were determined as described in the legend to Fig. 1. IP,
immunoprecipitation; IB, immunoblot.
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FIG. 6. A critical role of Etk in TNF-induced angiogenesis. BAEC in a 6-well plate were transfected with VC, Etk-SK, or Etk-DK, which
coexpresses an enhanced green fluorescent protein. Twenty-four hours postinfection, transfection efficiency and transgene expression were
determined. Cells were split into a 24-well plate to reach 100% confluency for migration and tube formation assays (see Materials and Methods).
(a) Expression of Etk-SK and Etk-DK was determined by Western blot with anti-Flag. (b) Etk-SK functions as a constitutive active form, whereas
Etk-DK functions as a dominant-negative form of Etk. VC, Etk-SK, and Etk-DK-expressing cells were treated with TNF (1 ng/ml for 15 min), and
activation of endogenous Etk was determined by immunoprecipitation with anti-Etk followed by Western blot with anti-phosphotyrosine. (c)
Etk-SK promotes, while Etk-DK inhibits, TNF-induced EC migration. Transfected BAEC were subjected to injury, and wound healing was
measured in the absence or presence of TNF (1 ng/ml) at 0, 12, and 24 h postinjury. Zero and 24 h in the presence of TNF are shown. Triplets
for each sample were performed. Experiments were repeated two times. (d) Quantitation of EC migration. Image capture and analyses were
performed as described in Materials and Methods. Data presented are means 
 standard errors of the means of the triplicate in one experiment.
Similar results from two other experiments were obtained. (e) Etk-SK promotes, while Etk-DK inhibits, TNF-induced EC tube formation.
Transfected cells were seeded in collagen gels as described in Materials and Methods in the presence or absence of TNF (1 ng/ml), and tubes were
visualized on day 5. Image capture and analyses were performed as described in Materials and Methods. Triplets for each sample were performed.
Experiments were repeated one time. (f) Quantitation of EC tube formation. Three images from each well were captured, and total tube areas
were measured in each field (30 mm2). Data presented are means 
 standard errors of the means of the two triplicates from two independent
experiments. IP, immunoprecipitation; IB, immunoblot.
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TRAF2-independent manner. Moreover, we show that Etk is a
critical mediator in TNF-induced angiogenesis by in vitro mod-
els of EC migration and EC tube formation. Our findings
demonstrate that Etk is the first kinase to associate specifically
with TNFR2 (but not with TNFR1).
EC are among the restricted cell types that express TNFR2
(6). The role of TNFR2 in TNF signaling in EC is not clear.
Here we show that TNF through TNFR2, but not TNFR1,
activates an EC-expressed kinase, Etk. This is supported by
several lines of evidence. First, an agonist to TNFR2, but not
to TNFR1, activates Etk in EC. Second, overexpression of
TNFR2, but not TNFR1, in EC activates Etk. Third, TNF fails
to activate Etk in TNFR2-deficient cells, but Etk activation by
TNF is still present in TNFR1-deficient cells.
It is generally accepted that TNF utilizes TNFR1 and
TNFR2 to trigger distinct signaling and to exert diverse bio-
logical functions in a context-dependent manner. TNFR1 is
believed to mediate cell death, whereas TNFR2 serves to pro-
mote cell activation, migration, growth, or proliferation (9, 36,
47, 52, 55, 56, 63). In T cells, TNF through TNFR2 promotes
T-cell proliferation at an early stage of activation (36). It has
been shown that TNFR2, but not TNFR1, is critical in TNF-
induced proliferation of oligodendrocyte progenitors and re-
myelination (1). However, the mechanisms by which TNF
through TNFR2 exerts these functions have not been defined.
The reason, in part, is that specific proteins recruited by
TNFR2 have not been identified. TRAF2 can be recruited to
both TNFR1 and TNFR2 signaling complexes (46, 47) and is
the only signaling molecule found to associate with TNFR2.
Several factors, including cellular inhibitor of apoptosis and
caveolin-1, are recruited to TNFR2 through TRAF2 (16, 46).
Thus, TRAF2 and TRAF2-associated factors have been impli-
cated in TNFR2-induced antiapoptotic or apoptotic responses.
In contrast to these findings, we show that TNF-induced
activation of Etk through TNFR2 is independent of TRAF2.
The interactions between Etk and TNFR2 are dependent on
the N-terminal portion (the PH, TH, and SH3 domains) of Etk
and the last 16 amino acids at the C-terminal intracellular
domain of TNFR2. This Etk-binding sequence is distinct from
the TRAF2-binding motif. Specifically, the TNFR2(16) de-
letion mutant lacking the last 16 residues retains TRAF2 bind-
ing but fails to associate with and activate Etk. Also, WT-
TRAF2 does not activate Etk, and DN-TRAF2 does not block
TNF-induced Etk activation.
An interaction between the Btk family and the TNFR family
has been demonstrated previously (59). Similar to Etk-TNFR2
interaction, Btk interacts with Fas, a member of the TNFR
family involved in apoptosis in a ligand-independent manner
(59). However, the association of Btk and Fas is dependent on
the PH and kinase domains but not on the SH3 domain of Btk.
This interaction disrupts the association of FADD with Fas,
leading to inhibited Fas-induced apoptosis. Consistent with
our finding, Btk does not interact with TNFR1 signaling com-
plex molecules such as TRADD, FADD, and FLICE (59).
The mechanism by which Etk is activated is not clear. On the
basis of data from Etk activation by focal adhesion kinase
(FAK), it has been proposed that integrin-induced binding of
the PH domain of Etk to the FERM domain of FAK leads to
conformational change of the PH domain and phosphorylation
of Y40 concomitant with the membrane translocation of Etk
(10). This process resembles the effects of phospholipid bind-
ing to the PH domains of Btk family kinases in response to
growth factors or cytokines. Membrane targeting of Etk will
open up the closed conformation of inactive Etk and will allow
the kinase to be phosphorylated by Src family kinases at the
highly conserved tyrosine residue Y566 in the catalytic domain,
which is originally masked by the PH domain. Tyrosine phos-
phorylation activates the Etk kinase, leading to autophosphor-
ylation and activation. We show that, unlike what is shown by
this two-step model, Etk forms a preexisting complex with
TNFR2 located in the cytoplasm membrane. This association
is independent of the phospholipid-binding PH domain of Etk,
as the phospholipid-binding deficient mutant (Etk-DN) still
binds to TNFR2. This membrane-bound Etk should still be in
a closed inactive form. TNFR2 has no kinase activity, and it is
not clear how Etk is activated in response to TNF. It has been
shown that TNFR superfamily can form preassembled trimers,
and ligand induces a conformation change (8). One possibility
for Etk activation by TNFR2 is that TNF-induced TNFR2
conformational change triggers a change in Etk conformation
to open up the closed conformation (Fig. 7). Alternatively,
TNF-induced recruitment of additional factor(s) (e.g., a ki-
nase) to a TNFR2/Etk complex, which phosphorylates Etk to
open up the closed conformation, resembling phosphorylation
of Y40 in the PH domain by FAK (10). The second step of Etk
activation in response to TNF has not been determined. The
FIG. 6—Continued.
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tyrosine phosphorylation of the kinase-inactive Etk (Etk-DK)
is undetectable in response to TNF/TNFR2, indicating that
Etk activation induced by TNF/TNFR2 is largely due to au-
tokinase activity. This is similar to Etk activation by interleu-
kin-6 (40).
Our data demonstrate that Etk plays an important role in
TNF-induced EC migration and tube formation by in vitro
models, suggesting that Etk is a critical mediator in TNF-
induced angiogenesis. The roles of Etk in cell activation, pro-
liferation, and migration have been demonstrated in other cell
types, including tumor cell lines and epithelial cells. Recently it
has been shown that expression of Etk is much higher in
metastatic carcinoma cells than in nonmetastatic carcinoma
cells (10). Mechanistic studies suggest that interactions of Etk
and FAK synergistically promote migratory potential of carci-
noma cells. Etk is highly expressed in cultured EC (HUVEC
and BAEC) (10 and our data) and in vivo endothelium (13).
However, the role of Etk in angiogenesis has not been eluci-
dated. Recent studies show that although Etk-deficient mice
have no obvious defect in vasculogenesis, Etk is activated by
EC growth factor receptor tyrosine kinases VEGFR1 and
Tie-2. These data led the authors to postulate that Etk has a
redundant function downstream of receptors for angiogenic
factor (41). Angiogenesis under pathological conditions (e.g.,
inflammation) has not been examined with mice. Our data
demonstrate that Etk mediates TNF-induced EC migration
and tube formation in vitro, implying that Etk may play a
critical role in inflammatory angiogenesis, such as occurs with
ischemia, atherosclerosis, and rheumatoid arthritis. Our stud-
ies suggest that Etk might be a target for treatment of the
inflammatory angiogenesis-dependent disease.
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